IP Library Granted Patent US 12,016,903
Granted Patent B2
US 12,016,903 · App. 15/528,350 · Granted Jun 25, 2024

Long-acting growth hormone treatment

Inventors: Kennett Sprogøe (Holte, DK); Henrik Egesborg (Hellerup, DK); Steen Jensen (Dragoer, DK); Thomas Kurpiers (Heidelberg, DE)
Assignee: ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S
A61K38/27A61K9/0019A61K9/19A61K47/60A61M5/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,016,903
App. No.
15/528,350
Granted
Jun 25, 2024
Kind
B2
Abstract

The present invention relates a pharmaceutical formulation comprising a long-acting growth hormone for use in a method of treating growth hormone deficiency, wherein the long-acting growth hormone formulation is administered to a patient in a bracketed dosage regimen, to a multitude of unit dosage forms comprising a long-acting growth hormone formulation, wherein the unit dosage forms comprise increasing amounts of growth hormone equivalents and wherein the amount of growth hormone equivalents increases by at least 10% between one unit dosage form and the next higher dosage form; their use in a method of treating growth hormone deficiency and method of treating growth hormone deficiency in a bracketed dosing regimen.

Claims (74)

1. A method of treating growth hormone deficiency in human children, the method comprising:

a step of administering to human children patients in need thereof a long-acting growth hormone formulation in a bracketed dosing regimen in which a range of patients' weights is allocated a particular dose of drug, which weight range is referred to as a “weight bracket”;

wherein dosage increases occur in a step-wise manner and wherein a bracketed dosage regimen has between 3 and 20 weight brackets;

wherein the dose a patient receives measured in mg hGH equivalents per week is the same for all patients within that weight bracket;

wherein the dose of one weight falling into each particular weight bracket corresponds to 0.24 mg/kg/week;

wherein patients of the same bracket having a lower weight receive a dose that is higher than said dose of the fixed dosage regimen and patient of the same bracket having a higher weight receive a dose that is lower than said dose of the fixed dosage regimen, wherein the dose received by a patient with the lowest weight within a bracket is 15-22% higher than the dose received by a patient with the highest weight within a bracket; and

wherein if a patient's weight exceeds the weight of a particular weight bracket the dose is increased to the dose of the next weight bracket, which dose of growth hormone equivalents in two neighboring brackets increases by at least 10%;

wherein the long-acting growth hormone formulation comprises a compound of formula IV:

wherein D is an hGH moiety having the amino acid sequence of SEQ ID NO: 1 connected to the rest of the molecule through an amine functional group; and p1, p2, p3 and p4 are independently selected from 200-250.

2. The method of claim 1 ;

wherein the long-acting growth hormone formulation is a lyophilized formulation that is reconstituted prior to administration.

3. The method of claim 1 ;

wherein the long-acting growth hormone formulation is a liquid formulation.

4. The method of claim 1 ;

wherein the long-acting growth hormone formulation is administered via a prefilled syringe.

5. The method of claim 1 ;

wherein the long-acting growth hormone formulation is administered via a pen injector.

6. The method of claim 1 ;

wherein the long-acting growth hormone formulation is contained in a dual chamber cartridge.

7. The method of claim 6 ;

wherein the dual chamber cartridge is utilized with a syringe to administer the long-acting growth hormone formulation.

8. The method of claim 6 ;

wherein the dual chamber cartridge is utilized with a pen device or electronic injector to administer the long-acting growth hormone formulation.

9. The method of claim 1 ;

wherein all increases between neighboring brackets are by a constant percentage value.

10. The method of claim 1 ;

wherein the bracketed dosage regimen comprises 3 to 15 brackets.

11. The method of claim 1 ;

wherein doses of the long-acting growth hormone formulation are administered to a patient with a time period of at least two days between two consecutive doses.

12. The method of claim 1 ;

wherein the bracketed dosing regimen of the long-acting growth hormone formulation is continued for a time period of at least 6 months.

13. The method of claim 1 ;

wherein doses of the long-acting growth hormone formulation are administered to a patient with a time period of seven days between two consecutive doses.

14. The method of claim 1 ;

wherein the dose of growth hormone equivalents in two neighboring brackets increases from 15 to 40%.

15. The method of claim 1 ;

wherein the dose of growth hormone equivalents in two neighboring brackets increases from 18 to 30%.

16. The method of claim 1 ;

wherein the bracketed dosage regimen has between 6 and 14 weight brackets.

17. The method of claim 1 ;

wherein the growth hormone deficiency is treated for a time period of at least 24 months.

18. The method of claim 1 , wherein the bracketed dosage regime has 12 brackets.

19. The method of claim 1 , wherein the bracketed dosage regime is supplied from nine unit dosages.

20. The method of claim 1 , wherein the weight brackets and their respective dosages comprise:

Weight

Dose

bracket

Mg/

(kg)

week

11.5-

3

13.9

14-

3.6

16.4

16.5-

4.3

19.9

20-

5.2

23.9

24-

6.3

28.9

29-

7.6

34.9

35-

9.1

41.9

42-

11

50.9

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2020
From: KURPIERS, THOMAS, DR.
To: ASCENDIS PHARMA GMBH
Reel/Frame 052792/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2020
From: SPROGØE, KENNETT, DR.; JENSEN, STEEN, DR.
To: ASCENDIS PHARMA A/S
Reel/Frame 052792/0872 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2020
From: EGESBORG, HENRIK, DR.
To: ASCENDIS PHARMA A/S
Reel/Frame 052792/0900 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2020
From: ASCENDIS PHARMA GMBH
To: ASCENDIS PHARMA A/S
Reel/Frame 052792/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2020
From: ASCENDIS PHARMA A/S
To: ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S
Reel/Frame 052793/0010 →
Priority Claims (1)
EP 14194248 · Nov 21, 2014 · regional
Continuity (1)
Related Publication 20170312342A1 · Nov 2, 2017